casopitant inntooltip international nonproprietary former tentative trade names rezonic us zunrisa europe receptor antagonist undergoing research treatment chemotherapyinduced nausea development july company filed marketing authorisation application european medicines agency application withdrawn development discontinued september glaxosmithkline decided safety assessment however review listed casopitant development potential novel antidepressant treatment major depressive disorder phase clinical trial drug article relating gastrointestinal system stub help wikipedia expanding drug article relating nervous system stub help wikipedia expanding httpsenwikipediaorgwikicasopitant